Our results show that RPE cells produced and released TSP-1 in
vitro and that TSP-1 accumulated in the cytoplasm of RPE cells in vitro
and in vivo.
Several different cell types are known to produce TSP-1. Among ocular
cells, corneal endothelial cells probably produce TSP-1, because
positive immunostaining for TSP-1 has been observed in
them.
14 40 Although corneal tissue is avascular, vascular
growth can be induced by several pathologic processes in which the
tissue’s physical structure or cell function are disturbed. It has
been suggested that corneal cells may play some role in maintaining the
transparency of the cornea by inhibiting vascular
growth.
41
Also, pathologic choroidal neovascularization with progression toward
the neuroretina is frequently seen in eyes in which RPE cells are
undergoing senescent functional and morphologic changes.
28 These findings suggest that RPE cells play a role of inhibiting
choroidal angiogenesis. TSP-1 is known to inhibit angiogenesis
profoundly, both in vivo and in vitro.
19 20 21 22 TSP-1
molecules and RPE cells coexist on the avascular epiretinal membrane in
several diseases.
26 27 Possible natural mechanisms for
halting angiogenesis have been found in vivo and in vitro. Cytokines
mediate cell-to-cell signals for regulating cell
proliferation.
42 43 Pericytes inhibit angiogenic activity
by contacting vascular endothelial cells through the activation of a
latent form of transforming growth factor-β.
44 45 46 Alteration of the extracellular matrix can induce morphologic changes
of angiogenic vascular endothelial cells, also halting
angiogenesis.
47 These findings suggest that RPE cells may
modulate choroidal vascular growth by supplying TSP-1.
Bornstein
48 has defined extracellular protein molecules
dedicated to modulation of cell behavior by interacting with many
extracellular molecules and with cell surface receptor as matricellular
proteins. TSP-1 was expressed by migrating RPE in proliferative
vitreoretinopathy membranes and RPE-derived TSP-1, together with other
matricellular proteins, has been considered to play a role in
development of proliferative vitreoretinopathy.
49 Our
results suggest an additional or alternative role for RPE-derived
TSP-1, because it is also expressed on nonmigratory RPE cells.
The biological influence of TSP on angiogenesis is still
controversial.
4 23 It has been reported that lower
concentrations of TSP-1 induces the tube formation of vascular
endothelial cells in vitro, whereas inhibition occurs in higher
concentrations. Furthermore, hypoxic stimulation and increased
concentration of extracellular matrices including TSP-1 enhance the
release of angiogenic growth factors as vascular endothelial growth
factor and fibroblast growth factor-2 by RPE cells.
50 It
is hard to determine whether the TSP-1 produced by RPE cells stimulates
or inhibits the angiogenesis in vivo. However, it has been clear that
neither choroidal blood vessels nor retinal blood vessels proliferate
and migrate toward the RPE layer though TSP-1 accumulated surrounding
the RPE layer. Therefore, TSP-1 may play some role in maintaining
differentiated blood vessels.
Although data are specific to TSP-1, it has been reported that the
biologic activity of all types of TSPs is similar,
51 52 and TSP-1 is the most prevalent TSP molecule found in vivo. Therefore,
it is reasonable to speculate that RPE cells may produce other
varieties of TSP. Also, TSP-1 may be produced by retinal cells other
than RPE cells. That there is no evident accumulation of TSP-1 on
retinal blood vessels and retinal neuronal and glial
cells
53 suggests that RPE cells are the major retinal
components producing TSP-1 physiologically.
Our study did not allow us to determine whether RPE cells in the
physiological state continuously produce TSP-1, although the positive
immunostaining of the intracellular TSP-1 of RPE layer suggests that
they do. However, a decrease of TSP-1 after an initial increase was
shown in both the cultured medium and mRNA of RPE cells. This finding
suggests that the production of TSP-1 may increase in pathologic
conditions involving RPE proliferation and migration. Decreased
production of TSP-1 in conditions of cellular quiescence as the cell
density increases has been reported for other TSP-producing
cells.
54 The decrease of TSP-1 on the culture medium may
be due to degradation after secretion. Furthermore, it is also known
that the antiangiogenic activity of TSP-1 is mediated by CD36, a
TSP-1–binding receptor.
55 56 57 TSP-1 expression has been
shown to be upregulated by stimulation to CD36. Several
TSP-1–producing cells express CD36,
58 suggesting that
TSP-1 is a factor in the autocrine–paracrine
mechanism.
42 43 Finally, it has been reported that CD36 is
expressed on RPE cells and mediates the modulatory action of
phagocytosis of RPE cells.
59 Further accumulation of
knowledge on modulation of TSP-1 production by RPE cells and its
biologic effects may elucidate key physiological maintenance mechanisms
and pathologic processes.